Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large

Executive Summary

Uncertainty about Brexit's impact on the FDA-EMA mutual recognition agreement are among issues worrying regulators as countdown continues to the UK's departure from the EU.
Advertisement

Related Content

New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit
US FDA To Rely On Inspections From More European Countries
UK Pharma Takes Hope From Draft Brexit Deal But Uncertainty Reigns
No-Deal Brexit: UK Can Wave Goodbye To Savings From Parallel Imports
UK And EMA Could Work Together Informally After Brexit
US FDA Recognizes Eight EU Authorities, Triggers Mutual Recognition Provisions
US FDA’s Foreign Inspection Agenda: Visit The 1,000 Facilities It’s Never Seen
Jenkins' Retirement From US FDA Was Several Years In The Making
FDA Encourages Pediatric Master Protocols With Bayesian Approach
FDA Posts OCI Agent In Singapore, But Other Foreign Offices Close

Topics

Advertisement
UsernamePublicRestriction

Register

PS124517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel